Stock NRBO NEUROBO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases NeuroBo Pharmaceuticals, Inc.

Equities

NRBO

US64132R4048

Real-time Estimate Cboe BZX
Other stock markets
 12:29:57 15/05/2024 am IST 		5-day change 1st Jan Change
4.08 USD +1.24% Intraday chart for NeuroBo Pharmaceuticals, Inc. +4.95% +9.02%
09/05 NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
08/05 Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NEUROBO PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
AQ
NEUROBO TO PRESENT LATEST PRE-CLINICAL DATA ON CARDIOMETABOLIC ASSETS, DA-1241 AND DA-1726, TARGETING MASH AND OBESITY, AT SCIENTIFIC CONFERENCES IN JUNE
AQ
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
PR
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
PR
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
PR
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
PR
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
PR
NeuroBo Pharmaceuticals : Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer - Form 8-K
PU
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
PR
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
PR
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
PR
NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
PR
NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
PR
NeuroBo to Participate in Industry and Investor Conferences in January
PR
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
PR
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
PR
NEUROBO TO PARTICIPATE IN INVESTOR CONFERENCES IN DECEMBER
AQ
NeuroBo to Participate in Investor Conferences in December
PR
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
PR
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NRBO Stock
  4. News NeuroBo Pharmaceuticals, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW